PBI-4050: Additional Phase II data

Data from 20 Type II diabetics with metabolic syndrome in an open-label, Canadian Phase II trial showed that once-daily 800 mg oral PBI-4050 reduced mean HbA1c by 0.75% in patients with a baseline HbA...